09:14     NORTHEAST TIGER<08197> - Quarterly Results Announcement             

                                                                              
    Northeast Tiger Pharmaceutical Company Limited announced on 13/05/2005:   
    (stock code: 08197 )                                                      
                                                                              
    Year end date                         :31/12/2005                         
    Currency                              :RMB                                
    Auditors' report                      :N/A                                
    1st Quarterly Report Reviewed by      :Audit Committee & Auditors         
                                                                              
    Important Note :                                                          
                                                                              
    This result announcement form only contains extracted information from    
    and should be read in conjunction with the detailed results announcement  
    of the issuer, which can be viewed on the GEM website at                  
    http://www.hkgem.com                                                      
                                                                              
                                               (Unaudited)       (Unaudited)  
                                                  Current Last Corresponding  
                                                   Period            Period   
                                           from 01/01/2005   from 01/01/2004  
                                             to 31/03/2005     to 31/03/2004  
                                                   RMB'000           RMB'000  
                                                                              
    Turnover                              :         11,409            10,302  
    Profit/(Loss) from Operations         :          (754)             (165)  
    Finance cost                          :          (357)             (340)  
    Share of Profit/(Loss) of Associates  :            N/A               N/A  
    Share of Profit/(Loss) of Jointly                                         
             Controlled Entites           :            N/A               N/A  
    Profit/(Loss) after Taxation & MI     :        (1,111)             (505)  
    % Change Over the Last Period         :            N/A                    
    EPS / (LPS)                                                               
              Basic (in dollar)           :    (RMB 0.001)       (RMB 0.001)  
              Diluted (in dollar)         :            N/A               N/A  
    Extraordinary (ETD) Gain/(Loss)       :            N/A               N/A  
    Profit (Loss) after ETD Items         :        (1,111)             (505)  
    1st Quarter Dividends per Share       :            NIL               NIL  
    (specify if with other options)       :            N/A               N/A  
    B/C Dates for 1st Quarter Dividends   :            N/A                    
    Payable Date                          :            N/A                    
    B/C Dates for (-) General Meeting     :            N/A                    
    Other Distribution for Current Period :            NIL                    
    B/C Dates for Other Distribution      :            N/A                    
                                           (bdi: both days inclusive)         
                                                                              
    For and on behalf of                                                      
    Northeast Tiger Pharmaceutical Company Limited                            
                                                                              
    Signature :                                                               
    Name      : Xu Zhe                                                        
    Title     : Chairman                                                      
                                                                              
    Responsibility statement                                                  
                                                                              
    The directors of the Company (the "Directors") as at the date hereof      
    hereby collectively and individually accept full responsibility for the   
    accuracy of the information contained in this results announcement form   
    (the "Information") and confirm, having made all reasonable inquiries,    
    that to the best of their knowledge and belief the Information are        
    accurate and complete in all material respects and not misleading and     
    that there are no other matters the omission of which would make the      
    Information herein inaccurate or misleading.The Directors acknowledge     
    that the Stock Exchange has no responsibility whatsoever with regard to   
    the Information and undertake to indemnify the Exchange against all       
    liability incurred and all losses suffered by the Exchange in connection  
    with or relating to the Information.                                      
                                                                              
    Remarks:                                                                  
                                                                              
    a. Accounting policy and basis of presentation                            
    The financial statements have been prepared in accordance with Hong       
    Kong Financial Reporting Standards (which also include Statements         
    of Standard Accounting Practice and Interpretations) issued by the        
    Hong Kong Institute of Certified Public Accountants ("HKICPA"),           
    accounting principles generally accepted in Hong Kong, and the            
    disclosure requirements of the Hong Kong Companies Ordinance and          
     the applicable disclosure provisions of the Rules Governing the          
    Listing of Securities on Growth Enterprise Market (the "GEM") of          
    The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules").        
                                                                              
    The financial statements have been prepared under the historical cost     
    convention except that certain fixed assets are stated at fair value.